Primary Myelofibrosis - 26 Studies Found Active, not recruiting : Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis : Myelofibrosis : 2012-12-24 : Drug: Peginterferon alfa-2a 50 mcg subcutaneous injection once per week Suspended : Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor : Primary Myelofibrosis : 2015-04-21 : Drug: Imetelstat 9.4 milligram/kilogram (mg/kg) Terminated : A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) : Primary Myelofibrosis : 2014-03-06 : Drug: Ruxolitinib Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. lo Completed : Thalidomide in Treating Patients With Myelofibrosis : Primary Myelofibrosis : 2001-05-06 : Drug: thalidomide Given PO Withdrawn : A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis : Primary Myelofibrosis : 2015-10-21 : Biological: Pacritinib QD (Once a day) Completed : Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis : Myelofibrosis : 2010-06-22 : Drug: APLIDIN (plitidepsin) Aplidin® (plitidepsin) ly Active, not recruiting : Decitabine in Treating Patients With Myelofibrosis : Primary Myelofibrosis Secondary Myelofibr : 2004-11-09 : Drug: Decitabine Given SC Recruiting : P1101 in Treating Patients With Myelofibrosis : Primary Myelofibrosis Secondary Myelofibr : 2015-02-17 : Other: Laboratory Biomarker Analysis Recruiting : Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg : Myelofibrosis : 2016-03-08 : Drug: Ruxolotinib Ruxolitinib Active, not recruiting : Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence : Primary Myelofibrosis : 2010-07-15 : Drug: Pomalidomide 0.5 mg Poma Next >>>